Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Helper T Cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Helper T Cells. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-001696-36 Sponsor Protocol Number: IL2REG Start Date*: 2019-10-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG)
    Medical condition: Depressive episode in course of mood disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10012402 Depressive episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006229-23 Sponsor Protocol Number: PTCLS-IDE Start Date*: 2022-04-07
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.
    Medical condition: peripheral T Cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003622 ATLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004630-29 Sponsor Protocol Number: FIL_VERT Start Date*: 2018-06-15
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PT...
    Medical condition: Patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-folli...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002418-38 Sponsor Protocol Number: LUMC2012-01 Start Date*: 2012-08-21
    Sponsor Name:Leiden University Medical Center
    Full Title: Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor
    Medical condition: Patients with AML, MDS, ALL, CML in accelerated phase or blastic transformation, CLL, MM or aggressive lymphoma, who underwent a (non) myeloablative allo-SCT with an unrelated donor.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10007838 CD4 lymphocytes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003526-80 Sponsor Protocol Number: CLSG-PTCL-CHEPA Start Date*: 2021-12-16
    Sponsor Name:Kooperativní lymfomová skupina, z.s.
    Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.
    Medical condition: Peripheral T-cell lymphomas (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10001414 Adult T-cell lymphomas/leukaemias HLT
    20.0 100000004851 10022704 Intestinal T-cell lymphomas HLT
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    21.0 100000004864 10002451 Angioimmunoblastic T-cell lymphoma NOS LLT
    21.0 100000004864 10001415 Adult T-cell lymphoma/leukaemia NOS LLT
    21.1 100000004864 10076434 Hepatosplenic gamma-delta T-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000572-15 Sponsor Protocol Number: EGF117268 Start Date*: 2013-07-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patie...
    Medical condition: The subjects participated in the EGF105485 study, a randomized, placebo-controlled study of lapatinib in HER2-positive early-stage breast cancer. During participation in this study, subjects had b...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003327-15 Sponsor Protocol Number: TIDAM Start Date*: 2022-02-21
    Sponsor Name:Erasmus MC
    Full Title: An open-label, 8-week, proof of concept trial on thymosin-α1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18).
    Medical condition: Primary immunodeficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003735-16 Sponsor Protocol Number: KILT Start Date*: 2021-09-14
    Sponsor Name:LYSARC
    Full Title: A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
    Medical condition: Relapsed/refractory PTCL KIR3DL2-positive patients after at least one previous line of systemic based regimen of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042980 T-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042979 T-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) ES (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000349-42 Sponsor Protocol Number: DurIRVac-1 Start Date*: 2021-03-26
    Sponsor Name:Sahlgrenska Academy, University of Gothenburg
    Full Title: Evaluation of the Durability of Immune Responses to SARS-CoV-2 Using Novel Rapid Spike Interferon-Gamma Release and Activation-Induced Marker Assays and Anti-Spike IgG Following COVID-19 Vaccination
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000446-20 Sponsor Protocol Number: SPARTAC 04/2/025 Start Date*: 2006-07-28
    Sponsor Name:Imperial College
    Full Title: A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    8 10020161 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000827-94 Sponsor Protocol Number: U-DANCE-anti-AML Start Date*: 2016-09-08
    Sponsor Name:UMC Utrecht
    Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial
    Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2015-001327-23 Sponsor Protocol Number: ITP0815 Start Date*: 2015-06-26
    Sponsor Name:Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and ...
    Medical condition: Primary Immune Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10043554 Thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001712-35 Sponsor Protocol Number: N/2013/67 Start Date*: 2015-09-01
    Sponsor Name:Centre Hospitalier Régional Universitaire de Besançon
    Full Title: ANTICANCER THERAPEUTIC VACCINATION USING TELOMERASE-DERIVED UNIVERSAL CANCER PEPTIDES IN METASTATIC NON SMALL CELL LUNG CANCER
    Medical condition: lung cancer non-small cell
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003303-14 Sponsor Protocol Number: DETACT Start Date*: 2023-02-16
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT)
    Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003078-15 Sponsor Protocol Number: D5180C00007 Start Date*: 2018-07-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asth...
    Medical condition: Severe uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004241-32 Sponsor Protocol Number: EDOLAS Start Date*: 2020-02-07
    Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI
    Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
    Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005652-42 Sponsor Protocol Number: IM103-319 Start Date*: 2013-09-30
    Sponsor Name:Charité, Universitätsmedizin Berlin
    Full Title: Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients
    Medical condition: Patients after renal transplantation with signs of drug intolerance to their immunsuppressive therapy are considered to be converted to Nulojix
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    14.1 10042613 - Surgical and medical procedures 10054980 Immunosuppressant drug therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020002-15 Sponsor Protocol Number: A3921061 Start Date*: 2010-11-15
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Medical condition: Moderate To Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (Completed) NL (Completed) FI (Prematurely Ended) ES (Completed) DK (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) AT (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA